Who is it for?
Digistain® analyses the infrared spectroscopic signature of tumour tissue to provide recurrence-risk information
Designed for invasive breast cancer patients who are:
Stage 1 - 2
HER2-
ER+
up to 3 positive lymph nodes
Digistain is intended for patients with ER-positive, HER2-negative, Stage 1 or 2 invasive breast cancer and no more than 3 involved lymph nodes.
Digistain Prognostic Score – Breast is an in vitro diagnostic test for professional use. The result is an estimate of the risk of recurrence and is probabilistic. It is used with, and does not replace, established clinico-pathological factors and clinical judgement. Treatment decisions remain with the treating clinician.